Although much remains to be analyzed, the identification of IDH mutations in diffuse gliomas, and more recently in acute myeloid leukaemia [63], provided new potential therapeutic targets and emphasized the increasingly compelling link between cancer biology and basic metabolic processes. This evidence concerns the gene IDH2 and acute myeloid leukemia.